We know our markets. And we suspect that the established industry likes to play with the good faith of consumers. Our approach is different: We rely on the alert pioneering spirit and common sense of our qualified employees and our shared vision.
In our research and development centers, in the development process, existing processes are first questioned and problems are analyzed from a bird's eye view. In the next step, we are working on developing solutions, even if these fundamentally question industry-specific processes.
But others can make great speeches better. Measure us by our actions. If you have any questions about Vetdrop or our medical and pharmaceutical developments, our sales structure or our service philosophy, we look forward to your direct questions and suggestions.
The increasingly frequent failure of the central organs is a direct consequence of the steadily increasing administration of painkillers, which is associated with systemic side effects and, if used for a long time, leads to poisoning.
Is that important?
No. No question about it - the pain medication serves a good cause, namely to alleviate immediate suffering. But the type of watering can-like presentation is inefficient. vetdrop TDA is an innovative delivery system that, instead of distributing them throughout the organism, transports active ingredients exactly to where they should arrive, e.g. in a diseased joint or a damaged tendon structure - without a needle and through all layers of the skin.
Vetdrop is created in an innovative R&D factory and stands for extraordinary results and easy handling.
Application tests with the Fraunhofer Institute for Molecular Biology impressively show how the system carries the most varied of molecules through all layers of the skin to the site of action. In fact, no other transdermal application system is able to transport molecules of similar size through the skin. A publicly funded study with the University of Zurich has shown how the Sytsem achieves local effective levels in the middle of the joint shortly after the first application on the patient.
This study also examined the potential of the system in building damaged cartilage and joint structures. Test animals treated with vetdrop TDA were significantly less likely to develop osteoarthritis than their peers.
Vetdrop TDA is not only suitable for the treatment of various problems in the musculoskeletal system and the skin of house and farm animals, but has also found widespread use in equine professional sports and, for example, in police dog teams due to its gentle and effective dosage form. vetdrop always pursues a 100% "clean sports" policy and does not allow any compromises when it comes to the welfare of the animals.
No, the TDA system works with a pressure of up to 0.15 MPa. This allows the TDA system to atomize the applied cartridges onto the skin. The relatively large particles that are on the skin are not released by the TDA cartridges. This prevents them from penetrating the skin. Nevertheless, you should implement the hygiene measures customary in the industry (cleaning / disinfection of the skin surface) before and after each treatment.
chronic pain symptoms
and immune diseases will be
administered orally or intravenously.
These dosage forms go with one
associated with a high risk of side effects, as high
systemic dosages are needed to be local
effective dosage concentrations too
Vetdrop TDA combats chronic
Complaints efficiently and avoids those
side effects relevant systemic
Drug administration. Vetdrop TDA enables
transdermal transport of even large molecules
at high local dosage and lower
systemic stress. The application achieved
the tissue and enhances the subtopical
Redox potential to prepare the cells
on the dose of active ingredient.
like plasters or gels often not in the
Are able to reach deeper layers of the skin,
Vetdrop TDA transports active ingredients
down to the synovial fluid of the joint and
at the same time combats inflammatory,
basic oxygen generating device, which
enriches the carrier substance with oxygen
and this mixture in one to the site of action
adapted application frequency with high
Speed and in defined microdroplets
applied on and through the skin. the
The carrier substance is application-related
with medicinal or herbal ingredients
enriched and very receptive to the
of the galenic formulation and the
physical parameters of the system from and
can thus be set precisely. (Skin cancer
The superiority of the system is just coming
when administering larger molecules for
Wear. In tests with the Fraunhofer Institute
for molecular biology, TDA “Cyclosporin
A ”successfully through all layers of the skin
transported. This has not been done with anyone before
transdermal application system only
possible to some extent
for veterinary therapy is wide-ranging
and grows because of the consistent
Research orientation of our company
constantly on. It currently includes the following
• A phyto-pharmaceutical anti-infl
ammatory carrier (drug-free)
• Oligo-structured glucosamine for the
Long-term treatment of structural and
degenerative processes on cartilage and
• Multimolecular hyaluronic acid for
Treatment of tendons and ligaments.
• Low molecular hyaluronic acid for
Treatment of wound healing disorders and
• Locally activating natural formulations for
targeted activation of microcirculation,
e.g. for use with muscular
• An ad-hoc formulation for therapy
lymphatic swellings and more acute
Stress injuries or from
Otematomas in the dog.
• A propolis-based active formulation for
Use for skin fungus and eczema.
Depending on the regulatory status
the product range differs in the
different markets. In individual countries
Synthetic drug formulations are also used
offered, which is currently still the European
Go through the approval process
protects the oxygen during use
from bacterial contamination and stimulates
in combination with the physical
Application parameters the local
Patented “pro-drug” components of the
Carriers interact with the oxygen
and improve the pharmaceutical effect
of the administered substance. During the
Application becomes the inner surface of the
Carriers greatly enlarged. The horny layer
is opened and from the applied drops
wandered through. The arrival at the site of action,
e.g. an inflamed joint
with a comparatively short delay.
The project is supported by the renowned Swiss innovation agency “KTI” and the North German Life Science Excellence Center “Norgenta”.
Our team consists of industry experts with decades of research experience. vetdrop TDA is the result of these efforts - for your benefit and for the well-being of your animals and patients
Active formulations for Vetdrop TDA is
the range of applications of the system is large.
It ranges from treating everyday
(Inflammation, strains, fiber tears,
muscular discomfort) about treatment
of skin problems (eczema, fungi and
Wounds) to long-term treatment
manifested degenerative phenomena
(Osteoarthritis of the joint). The mechanism of action is
always the combination of galenic
Formulation, pro-drug components,
physical stimulation by stimulating the
Microcirculation and cellular supply
The test substance (carprofen) could be detected shortly after use. Only what arrives in the cell can also have an effect in the cell. We have achieved an adequately effective concentration - and that without unnecessary stress on the organism. "
After studying veterinary medicine in Pisa and Munich, Dr. vet. med. Peter Kronen received his PhD from the University of Pisa. He continued his education in Boston (MA, USA) in order to later complete a residency in anesthesia and intensive care medicine at Cornell University (Ithaca, NY, USA). He was a lecturer for research and teaching assignments in Vietnam and Guam and at the University of California (Davis, CA, USA) before returning to Europe. In 2006 he founded his company VAS Veterinary Anesthesia Services and has worked at the University of Zurich since then
In this way, wound healing disorders caused by licking the animals or awkward ruffs are avoided. Even infected wounds heal within a very short time without any problems. In the case of othematomas (blood ear), the treatment quickly achieves freedom from pain and supports the spontaneous resorption of the hematoma.
In the musculoskeletal system, the traumatized tissue can be relieved of pain locally. The change can also be treated directly in older degenerative processes such as ossified outer ligaments, overstretching of the pastern joint or arthrosis of the large joints. Despite months of lameness in advance, the animals are often free of lameness after just a few treatments. The problem of side effects and contraindications of NASIDs can be avoided, especially in older animals, which usually suffer from kidney and heart problems. "
Jürgen Löcherbach is an experienced small animal practitioner who studied in Giessen. He has been running his practice in Erndtebrück since 1982. He has been working with vetdrop since 2008. His healing successes with the system have been published in various publications
In the meantime I have treated over 100 horses and several dogs. A very lasting treatment success was achieved. Impressive successes can also be seen with the dogs. I treat acute and chronic muscle, tendon and joint diseases and even the causes of lameness that were previously difficult or impossible to treat, such as inflammation of the hoof rolls, spar, bone cysts or even bone tears, can be treated. In my more than thirty years of practice, I have already used many therapy options and technologies. But the most animal-friendly - because painless, low-risk and free of side effects - and most effective form of treatment is, in my experience, vetdrop TDA.
Dr. med. vet. Ingbert Fries studied in Hanover, Vienna and Berlin. He has been working with vetdrop TDA since 2007. His therapy center, founded in 2003, is located south of Hamburg and enjoys an excellent reputation among horse practitioners.
To avoid systemic risks, the formulations are modulated in such a way that capillary exchange remains low, but local depth transport is guaranteed. The formulations always also contain an oily phase, which creates subepidermal active depots. Effective levels in the joint can be detected in the synovial fluid from the very first application. The therapy cycle, however, extends over several treatments, with a frequency that depends on the severity of the indication treated and the patient's therapy history.
In early 2010, a publicly funded study began on the effect of TDA treatments on degenerative joint diseases and cartilage problems. The study was carried out at the University of Zurich.
In 34 sheep, a massive defect was placed in the cartilage of the knee joint and so-called “microfractures” were then punched into the bone. This structure was used in several previous studies by the chair and subsequently induces osteoarthritis of the joint within a few weeks. The animals were divided into six comparison groups and treated for six weeks with vetdrop TDA and, in a comparison group, with systemic standard therapy (intravenous administration of active substance). Another group served as a reference and was only treated initially. The four TDA groups were treated with different active formulations in the TDA system (3 times a week), the systemically treated group with carprofen iv carprofen was also the indicator substance in the investigations.
The blood levels of the animals were checked every two days, the joint levels initially more frequently and later weekly. In addition, the pain behavior of the animals was documented and examined. Six weeks after the last treatment (12 weeks after the surgery) the animals were sacrificed and examined for changes in the cartilage and bone of the manipulated joint. The study was funded by the Swiss national innovation agency KTI and carried out according to the highest ethical standards. It was subject to the control of the Swiss ethics committee.
The animals were of the same origin and age and grew up under identical conditions. Due to the low systemic exposure, they could be used as animal feed. The results are clear:
• Reproducible and effective levels have been achieved.
• The relationship between systemic and local drug levels was 7-8 times better with TDA than with systemic therapy.
• The pain behavior observed in the animals treated with vetdrop TDA was better than that in the control groups.
• Animals treated with Vetdrop TDA showed significantly better structures at the edge of the cartilage defect than the animals in the comparison groups. The indicator substance was identical in both groups - carprofen.
Carprofen is an anti-inflammatory agent that is currently only available in systemic form. The difference achieved in the defect between the TDA-Carprofen group and the Carprofen-iv group is all the more astonishing. Interestingly, even the animals treated neutrally (without active ingredient) with the TDA system performed better than their conspecifics treated iv with carprofen - although carprofen is said to have a positive effect on cartilage structure. Due to the high social relevance and the quality of the results, a follow-up study is being carried out with the University of Zurich
Vetdrop TDA is the perfect symbiosis of physical and pharmaceutical effects. The device includes individually tailored application programs for the various clinical indications. It also enables the physical application of the galenic products true to the matrix with application parameters perfectly matched to the individual products. It was important to make our research findings applicable. Practical suitability is always in the foreground in all developments.
Where are the greatest challenges in the fight against degenerative processes?
Dr. Teslenko: It is absolutely necessary to supply the cells. Many developments rely on short-term application success through inflammation suppression. In doing so, the cause of the problem is neglected. And that's ultimately in the cell. With TDA, we always pay attention to the regenerative aspect of the therapy. In combating degeneration, there is no way around the combinatorial supply of the cell with active substances and oxygen. What counts is not the short-term appearance, but the long-term and measurable therapeutic success.
So the key to health lies in the cell?
Dr. Teslenko: In a sense, yes. However, health is a complex field and ultimately everyone is at most as healthy as they behave. It is important to have a holistic understanding of the problem areas and relationships in the organism. With TDA we not only fight hypoxia, which is harmful to cell biology, through the targeted, transcutaneous oxygen supply, we also balance the radical balance and supply the cell with essential nutrients and active ingredients and thus exert a positive influence on the regenerative potential of the system.
So it depends on the right mix?
Dr. Teslenko: Successful cell therapy absolutely requires various factors, which we cover holistically with TDA. We supply the cells with the necessary components. But TDA is more than a “mix” - we are talking about progressive processes that influence each other and work synergistically. Our research has validated the regenerative power of TDA in long-term studies. We are particularly pleased with the sustainability of the therapeutic success, which reflects the system-immanent superiority of our concept therapy
Dr. Teslenko has been researching the possibilities of skin-penetrating deep therapy since the 1970s. He is now head of research and thus also chief developer of all pharmaceutical preparations for the TDA system.
We control all processes and guarantee the highest quality
We researched alternatives, found out where there was room for improvement and asked whether we should cooperate with the large pharmaceutical companies. Ultimately, we came to the conclusion that no third-party process, no bought-in production technology and no externally contracted product development can meet our requirements and, above all, the requirements of our customers. That is why we do things ourselves - well and in a competent team. It starts with the design of the devices, which not only have to work in medical practices, stud farms or zoos, but also have to meet high practical standards, and does not end with our pharmaceutical vehicle formulations for a long time. TDA is a groundbreaking treatment concept and the result of hard and innovative work.
We create new processes and leave the well-trodden paths. In all development work, we face tough competition from marketing professionals and large corporations. But we only sell what we are convinced of down to the last detail. Our offer is honest, because for us only the result counts. We work with high-quality raw materials that we can trace back to the origin.
All formulations are tested for their effectiveness and tolerance. We stand for the quality of our products with our good name. And we back up our therapeutic statements not only with pretty sales brochures, but primarily with robust and complex studies